Infrastructure

API R&D:
Our focused API portfolio has made it possible for us to emerge as one of the most efficient and cost-effective manufacturers, globally. We serve the needs of our customers through API and intermediate facilities in Hyderabad. In addition to efficiently streamlining the manufacturing processes for the existing list of products, our R&D team has developed and commercialized several products and backward integrate as needed. We are committed to sustainable supply chain practices based on the principles of ethics, human rights and labour, health and safety, environment, and management systems. We plan to grow the API business by launching new products through backward integration into core molecules and by boosting our business in key geographies.

Pilot Plant:
100 ltr GMP model all glass assembly

API Manufacturing Facility:
A state-of-the-art API intermediates and API's manufacturing facility is under expansion.

Formulation R&D Centre
Powering Next-Generation Medicines Through AI-Driven Pharmaceutical Development
Purview Lifesciences operates a dedicated Pharmaceutical Formulation Research & Development Centre in Hyderabad, India — one of the world's foremost pharmaceutical innovation hubs. Our R&D centre serves as the scientific engine of the organisation, translating molecular potential into market-ready medicines across the full spectrum of complexity — from high-volume generics to proprietary novel delivery systems and drug-device combination products.

We develop pharmaceutical finished dosage formulations across three strategic categories: generics, branded generics, and novel specialty products — including complex niche formulations and drug-device combinations that demand the highest levels of scientific rigour and regulatory precision. Our portfolio spans three core dosage form platforms — Injectables, Liquid Orals, and Semi-Solid / Topical formulations — enabling us to serve a diverse global client and product base with a single, integrated R&D infrastructure.
,
At the heart of our development philosophy is a commitment to AI-driven pharmaceutical development — leveraging artificial intelligence and machine learning to fundamentally transform the way medicines are designed, optimised, and brought to market. By embedding AI across the formulation development lifecycle, we deliver meaningfully higher velocity, quality, and consistency at every stage — from pre-formulation screening and excipient compatibility to stability prediction, process optimisation, and regulatory dossier preparation. This capability, unique among Indian formulation R&D organisations, positions Purview Lifesciences as a partner of choice for companies seeking faster development timelines without compromising scientific integrity.

AI-Driven Development: Our Technology Edge:
Purview Lifesciences integrates AI and machine learning across the formulation development lifecycle — an embedded capability drawn from the Purview Group's proprietary software and AI platform. This is not a peripheral tool; it is a core development methodology that reshapes how our scientists work:

• Accelerated Pre-Formulation Screening — AI models predict excipient compatibility, solubility profiles, and API-excipient interactions in silico, reducing wet-lab screening cycles and material consumption.
• Formulation Optimisation — Machine learning-guided Design of Experiments (DoE) identifies optimal formulation variables faster and with greater precision than conventional statistical approaches.
• Lyophilization Cycle Design — Proprietary AI algorithms predict optimal freeze-drying parameters—primary and secondary drying temperatures, ramp rates, and shelf temperatures—reducing development cycles for lyophilized products.
• Stability Prediction — AI-driven stability modelling predicts long-term product stability from accelerated data, enabling earlier go/no-go decisions and more efficient ICH stability study design.
• Process Analytical Technology (PAT) Integration — Real-time process monitoring combined with AI-driven anomaly detection improves batch consistency and reduces rejection rates.
• Regulatory Intelligence — AI-assisted dossier preparation and regulatory gap analysis aligns submissions with current agency expectations, reducing first-cycle approval timelines.
• The cumulative effect is a development organisation that moves materially faster, makes better-informed scientific decisions, generates reproducible and defensible data, and ultimately delivers more products to patients sooner.

Our Mission
To improve access to medicines globally — by developing high-quality, affordable, and innovative pharmaceutical formulations at the velocity, consistency, and scientific standard that modern healthcare demands. Through the integration of deep formulation expertise, advanced delivery technologies, and AI-driven development tools, Purview Lifesciences is building a next-generation pharmaceutical R&D organisation that is as much a technology company as it is a science company.

Injectable Manufacturing Facility:
Purview Lifesciences is establishing a brand new, state-of-the-art injectable manufacturing facility in Hyderabad, India — purpose-built from the ground up to serve the evolving needs of global pharmaceutical companies, emerging biotech innovators, and specialty drug developers seeking a trusted, science-led Contract Research, Development & Manufacturing Organisation (CRDMO) and Contract Manufacturing Organisation (CMO) partner.

This is not a retrofitted legacy plant. Every square metre of our facility has been designed with one priority: your product's success — from the first development batch to full commercial supply, and across every injectable dosage form from the simplest aqueous solution to the most complex liposomal, nanoparticle, or drug-device combination product.

We understand that choosing a manufacturing partner is one of the most consequential decisions a pharmaceutical company makes. Our facility, our science, and our team are built to earn and sustain that trust — batch after batch, filing after filing, market after market.